Table 2.

Associations of MTR and MTHFR genotypes and gene promoter methylation: ORs (95% CIs) for comparisons of controls to cases with promoter methylation (M), to cases without methylation (UM), and case-case comparisons

MTR A2756G (rs1805087)
MTHFR A1298C (rs1801131)
MTHFR C677T (rs1801133)
AAAGGGAAACCCCCCTTT
Premenopausal
    E-cadherin
        M/U/control30/121/37015/44/1613/6/3119/73/25715/53/2334/18/4922/73/22715/68/2515/21/68
        M vs. controls*1.01.22 (0.64-2.31)1.22 (0.35-4.21)1.00.71 (0.37-1.35)0.89 (0.30-2.64)1.00.59 (0.31-1.13)0.71 (0.26-1.90)
        U vs. controls*1.00.83 (0.57-1.23)0.57 (0.23-1.40)1.00.67 (0.46-0.97)1.07 (0.60-1.92)1.00.82 (0.58-1.18)0.92 (0.53-1.59)
        M vs. U1.01.49 (0.74-3.02)2.24 (0.51-9.88)1.01.05 (0.52-2.12)0.62 (0.17-2.26)1.00.73 (0.36-1.48)0.78 (0.27-2.29)
    p16
        M/U/control42/109/37044/15/1611/8/3127/65/25719/49/2335/17/4924/71/22724/59/2518/18/68
        M vs. controls*1.00.87 (0.47-1.60)0.28 (0.04-2.13)1.00.77 (0.43-1.38)0.95 (0.36-2.56)1.01.01 (0.57-1.79)1.21 (0.52-2.79)
        U vs. controls*1.00.92 (0.62-1.36)0.84 (0.38-1.88)1.00.65 (0.44-0.94)1.06 (0.58-1.92)1.00.70 (0.49-1.01)0.77 (0.44-1.37)
        M vs. U1.00.93 (0.47-1.83)0.31 (0.04-2.61)1.01.16 (0.61-2.24)0.96 (0.32-2.84)1.01.45 (0.76-2.78)1.55 (0.60-4.00)
    RAR-β2
        M/U/control37/114/37022/37/1611/8/3125/67/25716/52/2336/16/4925/70/22725/58/2515/21/68
        M vs. controls*1.01.39 (0.80-2.42)0.33 (0.04-2.49)1.00.52 (0.28-0.95)0.91 (0.36-2.25)1.00.81 (0.47-1.41)0.58 (0.22-1.55)
        U vs. controls*1.00.75 (0.50-1.13)0.80 (0.36-1.80)1.00.74 (0.51-1.09)1.09 (0.59-2.00)1.00.75 (0.52-1.09)0.99 (0.57-1.71)
        M vs. U1.01.86 (0.97-3.55)0.45 (0.05-3.92)1.00.76 (0.39-1.50)0.96 (0.34-2.69)1.01.04 (0.55-1.94)0.56 (0.19-1.63)
Postmenopausal
    E-cadherin
        M/U/control69/271/84732/135/4583/26/6241/176/60748/171/5467/37/13942/187/58642/180/56516/47/155
        M vs. controls*1.00.91 (0.59-1.39)0.66 (0.23-2.15)1.01.24 (0.83-1.86)0.72 (0.32-1.62)1.01.07 (0.70-1.63)1.46 (0.81-2.63)
        U vs. controls*1.01.00 (0.79-1.26)1.47 (0.91-2.38)1.00.99 (0.79-1.24)0.85 (0.57-1.26)1.01.04 (0.83-1.31)0.98 (0.69-1.41)
        M vs. U1.00.89 (0.56-1.41)0.43 (0.13-1.49)1.01.20 (0.78-1.86)0.84 (0.36-2.00)1.01.02 (0.65-1.62)1.50 (0.78-2.88)
    p16
        M/U/control86/254/84741/126/45810/19/6253/164/60757/162/54612/32/13959/169/58650/172/56523/40/155
        M vs. controls*1.00.92 (0.63-1.36)1.76 (0.57-3.56)1.01.04 (0.73-1.50)0.87 (0.46-1.65)1.00.89 (0.61-1.30)1.47 (0.89-2.43)
        U vs. controls*1.01.00 (0.78-1.27)0.76 (0.87-3.56)1.01.04 (0.82-1.31)0.81 (0.53-1.22)1.01.10 (0.88-1.39)0.93 (0.61-1.36)
        M vs. U1.00.90 (0.59-1.38)1.55 (0.69-3.50)1.00.97 (0.65-1.45)1.08 (0.53-2.22)1.00.82 (0.54-1.26)1.61 (0.89-2.89)
    RAR-β2
        M/U/control93/247/84744/123/4589/20/6254/163/60772/147/5469/35/13968/160/58662/160/56511/52/155
        M vs. controls*1.00.92 (0.64-1.33)1.46 (0.70-3.03)1.01.35 (0.94-1.91)0.67 (0.33-1.37)1.00.96 (0.68-1.37)0.61 (0.43-0.88)
        U vs. controls*1.01.00 (0.79-1.27)1.25 (0.74-2.11)1.00.93 (0.74-1.18)0.88 (0.59-1.31)1.01.08 (0.85-1.38)1.27 (0.66-2.45)
        M vs. U1.00.90 (0.60-1.37)1.20 (0.52-2.75)1.01.45 (0.98-2.13)0.68 (0.30-1.54)1.00.87 (0.58-1.29)0.48 (0.24-0.97)
  • * ORs and 95% CIs adjusted for age and race.

  • ORs and 95% CIs also adjusted for ER status.